FindTrial
Sign In

Long-term study of HP-3060

Long-term study of HP-3060 in patients with perennial allergic rhinitis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222924
Enrollment
Unknown
Registered
2015-07-30
Start date
2015-07-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial allergic rhinitis

Interventions

investigational material(s) Generic name etc : HP-3060 (Emedastine fumarate) INN of investigational material : emedastine Therapeutic category code : 269 Other agents for epidermis Dosage and Administ

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with a diagnosis of perennial allergic rhinitis and symptoms of this condition for at least two years.

Exclusion criteria

Exclusion criteria: - Patients with rhinosinusitis or with types of rhinitis other than allergic rhinitis, including vasomotor rhinitis and non-allergic rhinitis with eosinophilia. - Patients receiving hyposensitization therapy or nonspecific immunotherapy who have not reached the maintenance stage.

Design outcomes

Primary

MeasureTime frame
Safety—

Secondary

MeasureTime frame
Efficacy, and pharmacokinetics—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026